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Berg, Michaela, Stefan Offermanns, Roland Seifert, 
and Giinter Schultz. Synthetic lipopeptide Pam$ysSer(Ly& 
is an effective activator of human platelets. Am. J. Physiol. 266 
(Cell Physiol. 35): C1684-C1691, 1994.-Lipopeptide ana- 
logues of the NH2-terminus of bacterial lipoprotein are known 
to induce activation of macrophages, neutrophils, and lympho- 
cytes. We studied the effect of the lipopeptide N-palmitoyl-S- 
[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-(S)-seryl- 
(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine [Pam3CysSer(Lys)4] on 
several functions of human platelets. Pam3CysSer(Lys)4 led to 
the aggregation of platelets and induced the secretion of 
serotonin with an effectiveness similar to thrombin. These 
cellular effects of Pam&ZysSer(Lys)4 were concentration depen- 
dent, being half maximal at 2-3 PM and maximal at lo-30 
PM. Another lipopeptide also induced platelet aggregation and 
serotonin secretion but was less potent and less effective than 
Pam&ysSer(Ly& The lipid moiety and the peptide moiety of 
Pam$ysSer(Lys)4 alone were without any effect. Lipopeptides 
also stimulated tyrosine phosphorylation of several proteins 
with molecular masses similar to those found to be tyrosine 
phosphorylated in response to thrombin, and Pam3- 
CysSer(Lys)4 led to an increase in the cytosolic calcium 
concentration. All studied responses of platelets to lipopep- 
tides were inhibited by the prostacyclin receptor agonist 
cicaprost. Taken together, our data show that lipopeptides are 
effective activators of human platelets and that this activation 
is susceptible to the action of physiological platelet inhibitors. 
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UNDER NORMAL CONDITIONS, human platelets circulate in 
the blood as resting cells. Platelets can be activated by a 
variety of stimuli. Activation of platelets ultimately 
leads to their aggregation and to the release of pre- 
formed mediators such as serotonin. Many of the bio- 
chemical events that accompany their activation process 
have been well described (for review see Refs. 16, 30). 
The initial response of platelets toward many activating 
stimuli involves the rapid hydrolysis of inositol phospho- 
lipids with the release of inositol 1,4,5trisphosphate, a 
consecutive increase in cytosolic calcium concentration 
([Ca’+]i), and activation of protein kinase C. More 
recently, rapid changes in tyrosine phosphorylation of 
platelet proteins have been recognized to be an impor- 
tant early mechanism during platelet activation (29). 
The outer membrane of gram-negative bacteria con- 
tains lipoprotein as one of its major components (5). 
Bacterial lipoprotein carries a characteristic moiety at 
the NH2-terminus, consisting of one amide-linked and 
two ester-linked fatty acids attached to S-(2,3-dihydroxy- 
propyl)-cysteine. Synthetic lipopeptide analogues of the 
NH2-terminus of bacterial lipoproteins are activators of 
lymphocytes (3), macrophages (12), and neutrophils 
(28). No cellular receptor for lipoprotein or synthetic 
lipopeptide analogues has so far been described, and the 
molecular mechanisms involved in the cellular activa- 
tion by lipopeptides are not well understood. In macro- 
phages, lipopeptides have been shown to lead to an 
increase in [Ca2+]i (13), and activation of the membrane- 
bound form of protein kinase C was observed in B-cells 
(4). In myeloid cells, lipopeptides are effective stimula- 
tors of tyrosine phosphorylation (2 1). 
To extend the knowledge about the biological actions 
of lipopeptides, we studied the effect of synthetic lipopep- 
tides on several functions of human platelets and found 
them to be very effective platelet activators. 
MATERIALS AND METHODS 
MateriaZs. Lipopeptides N-palmitoyl-S-[2,3-bis(palmitoy- 
loxy)-(2RS)-propyl]-(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl- 
(S)-lysyl-(S)-lysine [Pam$ysSer(Ly&] andN-palmitoyl-S-[2,3- 
bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-(S)-alanyl-(S)- 
glycine [Pam&ysAlaGly] as well as Pam&ys coupled to 
polyethylene glycol [Pam&ysPEG] and the hexapeptide Cys- 
Ser(Ly& were from Rapp Polymere (Tubingen, Germany). 
Thrombin and genistein were from Sigma (Deisenhofen, Ger- 
many). [3H]serotonin was from Du Pont-New England Nuclear 
(Bad Homburg, Germany). Cicaprost (ZK 96 480) was a gift of 
Drs. E. Schillinger and K. H. Thierauch (Schering, Berlin, 
Germany). Polyclonal antiphosphotyrosine antisera were gen- 
erated and affinity purified according to Kamps and Sefton 
(14) with modifications (20). 
Isolation of platelets. Venous blood was collected from 
healthy drug-free volunteers and anticoagulated with 6 mM 
citric acid-12 mM sodium citrate. Platelet isolation was carried 
out at room temperature. Platelet-rich plasma was obtained by 
centrifugation of whole blood for 20 min at 200 g. Platelet-rich 
plasma was adjusted with citrate buffer to pH 6.5 and centri- 
fuged again two times for 15 min at 200 g to remove 
contaminating cells. Thereafter, platelets were pelleted by 
centrifugation for 10 min at 700 g and washed once in (in mM) 
23.5 glucose, 133 NaCl, and 6 citric acid-12 sodium citrate. 
Washed platelets were carefully resuspended in Hanks’ buffer 
devoid of calcium [in mM: 138 NaCl, 6 KCl, 1 MgC12, 1 
Na2HP04, 5 NaHC03, and 5.5 glucose, as well as 0.1% (wt/vol) 
bovine serum albumin and 20 mM N-2-hydroxyethylpiperazine- 
2V’-2-ethanesulfonic acid-NaOH (pH 7.4)]. 
Measurement of pLatelet aggregation and serotonin release. 
For measurement of platelet aggregation, washed platelets 
were preincubated in Hanks’ buffer containing 1 mM CaClz 
and 0.1% (wt/vol> bovine serum albumin for 3 min, and 
incubation was started by addition of stimuli. Platelet aggrega- 
tion was monitored using a four-channel lumiaggregometer 
(Aggrecorder II PA-3220; Kyoto Daiichi Kagaku, Kyoto, Ja- 
pan). 
For determination of serotonin release, anticoagulated plate- 
let-rich plasma was incubated for 10 min at 37°C and for 30 
min at room temperature in the presence of 50 nM [3H]seroto- 
nin (35 kBq/ml). Thereafter, platelets were loaded on a gel 
filtration column (Sepharose 2B-CL; Pharmacia, Freiburg, 
Germany) equilibrated with Hanks’ buffer without CaCIB, and 
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gel-filtrated platelets were collected. Preincubation of gel- 
filtrated platelets for 3 min at 37°C was started by addition of 
CaClz (1 mM final concentration). Immediately before addition 
of stimuli, imipramine was added at a final concentration of 2 
FM. Incubation of samples (130 ~1 final vol) was conducted for 
the time periods indicated in the figure legends and was 
stopped by the addition of ice-cold 3 1 mM ethylene glycol-bis(P- 
aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA) and 
633 mM formaldehyde (final concentrations). Samples were 
placed on ice and were centrifuged at 4°C for 15 min at 3,000 g. 
The amount of released [3H]serotonin was determined by 
scintillation counting of the resulting supernatant fraction. 
Unstimulated platelets were lysed in 1% (vol/vol) Triton 
X- 100, and cell-associated radioactivity was determined. The 
percent serotonin release is referred to as the total amount of 
[“H lserotonin present in unstimulated cells. 
Determination of [Ca2 ‘/;a Washed platelets were incubated 
for 30 min at 37°C in the presence of 4 PM of the acetoxy- 
methyl ester of fura 2. Thereafter, platelets were diluted with 
a 20-fold volume of Hanks’ buffer without CaCls containing 
citrate buffer (see above). After washing of platelets (700 g for 
10 min), platelets were suspended in Hanks’ buffer without 
CaClz, and preincubation for 3 min at 37°C was started by 
addition of CaCls (1 mM final concentration). Fluorescence 
was determined at 37°C with constant stirring of the cells 
using a Ratio II spectrofluorometer (Aminco, Silver Spring, 
MD) as described in Ref. 27. The excitation and emission 
wavelengths were 340 and 500 nm, respectively. 
Preparation ofplatelet lysates and immunoblotting. Washed 
platelets were preincubated for 3 min at 37°C in a final volume 
of 40 ~1. Incubation was initiated by addition of stimuli. 
Incubation was stopped by adding 20 c_~l of lysis buffer 16% 
(wt/vol) sod’ mm dodecyl sulfate (SDS), 18% (vol/vol) 2-mercap- 
toethanol, 30% (vol/vol) glycerol, 1 mM Na3V04, and a trace 
amount of bromophenol blue dye in 200 mM tris(hydroxymeth- 
yl)aminomethane-HCl (pH 7.5)]. Samples were immediately 
incubated for 8 min at 100°C and subjected to SDS-polyacryl- 
amide gel electrophoresis with separating gels containing 9% 
(wt/vol) acrylamide. Transfer of proteins onto nitrocellulose 
filters and detection of phosphotyrosine-containing proteins 
by the use of anti-phosphotyrosine antibodies and the chemilu- 
minescence (ECL) Western blotting detection system (Amer- 
sham, Braunschweig, Germany) have been described previ- 
ously (21). 
\ \ thrombin 
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Miscellaneous and reproducibility. Protein was determined 
using the bicinchoninic acid Protein Assay System (Pierce, 
Rockford, IL). Experiments shown are representative for at 
least three independently performed experiments using plate- 
lets from different donors. 
RESULTS 
Incubation of human platelets with 30 PM 
PamsCysSer(Lys)d led to the rapid aggregation of plate- 
lets (Fig. IA). Pam3CysSer(Lys)4 was as effective as was 
1.5 U/ml thrombin. Although Pam&ysSer(Ly&in- 
duced aggregation was maximal after -3-4 min, ag- 
gregation induced by thrombin did not reach a maxi- 
mum until 10 min. The lipopeptide Pam$ysAlaGly 
(30 PM), which differs in its peptide moiety from 
Pam$ysSer(Ly&, also induced platelet aggregation. 
However, aggregation of platelets in response to Pam3- 
CysAlaGly occurred more slowly than Pam$ysSer( Lys)*- 
induced aggregation, and Pam$ysAlaGly was less effec- 
tive. 
Figure 1B shows a concentration-response relation- 
ship of the effect of Pam&ysSer(Lys), on platelet aggre- 
gation. The effectiveness and the velocity of the lipopep- 
tide-induced platelet aggregation increased with 
increasing concentrations of Pam&ysSer(Lys)+ Plate- 
let aggregation in response to Pam$ysSer(Ly& and 
thrombin was markedly reduced in the absence of 
calcium, indicating that aggregation induced by these 
stimuli is dependent on the presence of extracellular 
calcium (Fig. 1C). 
To test the effect of lipopeptides on the release of 
mediators from platelets, platelets were loaded with 
[3H]serotonin, and [3H]serotonin release was measured 
after addition of stimuli (Fig. ZA). Pam3CysSer(Lys)d 
(30 PM), like thrombin (1.5 U/ml), led to a nearly 
maximal release of [3H]serotonin. The release of [3H]se- 
rotonin in response to Pam3CysSer(Ly& occurred very 
rapidly, being half maximal after < 0.5 min. Half- 
maximal release induced by thrombin was observed 
after - 1 min. Lipopeptide Pam3CysAlaGly was less 
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Fig. 1. Effects of lipopeptides on plate- 
let aggregation. About 1 x lo7 platelets 
were incubated under indicated condi- 
tions, and platelet aggregation was mea- 
sured as described in MATERIALS AND 
METHODS. A: platelets were incubated 
with 30 PM Pam$ysSer(Lys)d and 
Pam$ysAlaGly or with 1.5 U/ml throm- 
bin. B: effect of increasing concentra- 
tions of Pam$ysSer(Lys)4 on platelet 
aggregation. C: platelets were either in- 
cubated in presence of extracellular 
CaClz with 1.5 U/ml thrombin or 10 FM 
Pam$ysSer(Lys)4 or in buffer devoid of 
CaClz and supplemented with 3 mM 
EGTA [thrombin + EGTA, Pam:j- 
CysSer(Lys)J + EGTA]. Control: traces 
recorded in absence of any agonist. 
Shown is increase in light transmission 
of platelet suspension in relation to time 
after addition of stimuli. See text for 
definition of synthetic lipopeptides. 
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Fig. 2. Effects of lipopeptides on serotonin release in 
human platelets. About 1 x lo7 platelets were incubated 
under indicated conditions. Incubation of platelets with 
]“Hlserotonin and determination of released [“Hlseroto- 
nin were performed as described in MATERIALS AND 
METHODS. A: [“HJserotonin-loaded platelets were incu- 
bated with 30 PM lipopeptides Pam&ysSer(Lys)d and 
Pam$ysAlaGly, with 1.5 U/ml thrombin, or in absence 
of stimuli (control) as indicated for increasing time 
periods. B: platelets were incubated with increasing 
concentrations of Pam$ysSer(Lys)A and PamsCysAlaGly 
for 15 min. Values are means + SE of triplicates. 
loo 
0 
effective with regard to its ability to release serotonin, 
and the maximal effect was not reached until 45 min 
after addition of the lipopeptide. The effect of both 
lipopeptides occurred in a concentration-dependent man- 
ner (Fig. 2B). Pam3CysSer(Lys)4 was more potent and 
more effective than Pam&ysAlaGly with regard to 
stimulation of serotonin release. Although 
Pam&ysSer(Ly& induced serotonin release at a half- 
maximal concentration of 2-3 PM, half-maximal effec- 
tive concentrations of Pam&ysAlaGly amounted to 
-20 PM. 
Figure 3A shows the effect of Pam3CysSer(Lys)4 at 
increasing concentrations on [Ca2+]i. Pam&ysSer(Lys)* 
elevated [Ca2+]i in a concentration-dependent manner 
from a basal level of - 100 nM to - 1 PM at a lipopeptide 
concentration of 10 PM. The increase in [Ca”+]i caused 
by 10 PM of the lipopeptide was rapid in onset and was 
sustained. Similar to the effect of thrombin on [Ca2+]i 
(Ref. 23 and Fig. 3B), the magnitude of the rise in [Ca2+]i 
induced by Pam&ysSer(Lys)4 was greatly reduced in 
the absence of extracellular Ca2+ (see Fig. 3B), suggest- 
ing that a part of the increase in [Ca2+]; occurred via an 
influx of calcium ion from the extracellular space. 
Because platelet activation by different agents is 
known to involve the reversible phosphorylation of 
several platelet proteins on tyrosine residues (7, 9, 19>, 
we tested the effect of lipopeptides on tyrosine phosphor- 
ylation in human platelets. PamsCysSer(Lys)d and 
Pam&ysAlaGly at 30 PM induced tyrosine phosphoryla- 
A 
with 5 PM Pam&ysSer(Lys)4 (P) and 1.5 U/ml thrombin 
(T), or incubation was performed in absence of CaCl2 in 
7 
buffer containing 1 mM EGTA with same concentrations g I 
Fig. 3. Effect of Pam$ysSer(Lys)4 on cytosolic calcium 
concentration ([Ca”+]i) in human platelets. Platelets 
were loaded with acetoxymethyl ester of fura 2, and 
1000 
effect of stimuli on ]Ca2+ ]i was measured as described in 
MATERIALS AND METHODS. A: effect of indicated increasing 
concentrations of Pam&ysSer(Lys)4 on [Ca2+]i. B: plate- s 
lets were incubated in presence of extracellular CaClz = 300 ._ 
- 0 
0.17 0.33 0.67 1.33 2.5 5 15 45 
time [min] 
of Pam&ysSer(Lys)4 (P + E> and thrombin (T + E). 
Arrowheads: addition of stimuli. 
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tion of several proteins with molecular masses between 
29 and 170 kDa (Figs. 4 and 5). Proteins found to be 
tyrosine phosphorylated in response to both lipopep- 
tides exhibited molecular masses very similar to pro- 
teins tyrosine phosphorylated after addition of throm- 
bin. Pam&ys coupled to polyethylene glycol and the 
hexapeptide CysSer(Lys)4 were without effect on tyro- 
sine phosphorylation (Fig. 4A). The effect of 
Pam&ysSer( Lys)4 and Pam&ysAlaGly occurred in a 
concentration-dependent manner (Fig. 4B and data not 
shown, respectively). Pam&ysSer( Ly& was maximally 
effective with regard to tyrosine phosphorylation at a 
concentration of - 10 PM, and, like the effect of 
PamsCysSer(Lys)d on platelet aggregation and seroto- 
nin release, Pam&ysSer(Ly&-induced tyrosine phos- 
phorylation was observed very shortly after addition of 
the lipopeptide (Fig. 5). Tyrosine phosphorylation in 
response to Pam3CysSer(Lys)4 was detectable after 10 s, 
and tyrosine phosphorylation of most proteins reached a 
plateau after - 30-90 s, whereas tyrosine phosphoryla- 
tion in response to Pam&ysAlaGly was detectable not 
until 3-5 min after addition of the lipopeptide (data not 
shown). There are no obvious differences between the 
proteins tyrosine phosphorylated after addition of 
Pam$ysSer(Lys), and thrombin, and increased tyro- 
sine phosphorylation in response to Pam&ysSer(Lys)4 
and thrombin occurred with similar time courses. 
In a series of experiments we tested whether the lipid 
moiety or the peptide moiety of Pam3CysSer(Lys)4 alone 
B 
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Fig. 4. Tyrosine phosphorylation stimu- 
lated by lipopeptides in human plate- 
- 94 lets. Platelets (6-7 X 107/tube1 were 
incubated in absence or presence of 
- 67 
stimuli, platelets were lysed, and pro- 
teins were analyzed as described in MATE- 
RIALS AND METHODS. A: platelets were 
incubated for 20 min in presence of 1.5 
- 43 
U/ml thrombin (T), 30 pM Pams- 
CysSer(Lys)d (P&SL& 30 pM PamaCys 
(P&j, 30 FM CysSer(Lysl4 (CSL& 30 
pM PamaCysPEG (PaCPG), and 30 pM 
PamaCysAlaGly (PsCAG). B: effect of 
- 30 
increasing concentrations (p,M, abscissa) 
of PamsCysSer(Lysl4 on tyrosine phos- 
phorylation of platelet proteins. Shown 
are autoluminograms of blots. Numbers 
on left and right indicate molecular 
masses of marker proteins &Da). See 
text for definitions. 
Pam3CysSer (Lys)4 
was able to induce platelet activation. Neither the lipid 
moieties Pam&ys and Pam&ysPEG nor the hexapep- 
tide CysSer(Lysj4 led to platelet aggregation or seroto- 
nin release in human platelets (Table 1). Each substance 
was tested at concentrations to 100 p,M (data not 
shown). 
To study the relevance of lipopeptide-induced tyrosine 
phosphorylation, we assessed the effect of the tyrosine 
kinase inhibitor genistein (1) on lipopeptide-induced 
platelet activation. Genistein has been shown to inhibit 
activation of platelets induced by different stimuli (6,2). 
Figure 6A shows the effect of genistein (30 and 100 PM) 
on Pam&ysSer(Lysj4- and thrombin-induced tyrosine 
phosphorylation. Preincubation of platelets with 100 
PM genistein blocked the effect of Pam&!ysSer(Ly& 
and considerably inhibited the effect of thrombin on 
tyrosine phosphorylation. Genistein at the same concen- 
tration led to the marked inhibition of lipopeptide- and 
thrombin-induced platelet aggregation (Fig. 6, B and C, 
respectively) and serotonin release (Fig. 6D). In all cases 
the inhibitory effect of genistein toward Pam3- 
CysSer(Lys)4-induced responses was more pronounced 
than toward thrombin effects. Although inhibition of 
aggregation induced by both stimuli was almost com- 
plete after preincubation of platelets with 300 FM 
genistein, 300 p,M genistein by itself released some 
170 - 
116 - 
76 - 
- 67 
Fig. 5. Time course of Pams- 
CysSer(Lys)d- and thrombin-induced ty- 
rosine phosphorylation in human plate- 
lets. Platelets (6-7 x 107/tube) were 
1 43 
incubated with 30 I.LM PamsCys-Ser- 
(Lys)~ (P) or 1.5 U/ml thrombin (T) for 
indicated time periods. Samples were 
processed as described in MATERIALS AND 
METHODS. Shown is autoluminogram of 
~ 36 blot with molecular masses of standard 
proteins (kDa) on left and rig&. DF, dye 
front; c, control (without stimulus). 
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Table 1. Effect of different substances on platelet 
aggregation and serotonin release from platelets 
Condition 
Platelet Serotonin 
Aggregation, % Release, % 
Thrombin 96.0 f 3.8 99.8 -c 0.7 
PamsCysSer(Lys)d 91.725.8 98.3 -c 1.0 
CysSer(Ly& 4.3 k 3.7 a.7 e 0.3 
Control 4.0 k 5.4 8.8 zt 1.4 
PamsCys 6.5 z!z 4.3 8.1* 0.5 
PamsCysPEG 4.3 k 3.3 8.620.7 
PamXvsAlaGlv 50.2 k 5.2 12.5” 1.0 
Values are means ? SD of triplicates. Platelet aggregation and 
serotonin release were measured 10 min after addition of stimuli as 
described in Figs. 1 and 2 and MATERIALS AND METHODS. Thrombin was 
used at a concentration of 1 U/ml, and all other substances were 
applied at a concentration of 30 pM. Control, without stimulus. See 
text for other definitions. 
[3H]serotonin from platelets, indicating that genistein 
at this concentration may lead to unspecific effects. The 
effect of genistein on a lipopeptide-induced rise in [Ca2+]i 
could not be studied since genistein interfered with 
fluorescence measurements. 
We further studied the effect of the prostacyclin 
receptor agonist cicaprost on Pam3CysSer(Lys)4-in- 
duced platelet activation. Prostacyclin receptor-medi- 
ated elevation of the intracellular adenosine 3’,5’-cyclic 
monophosphate (CAMP) concentration is one of the 
physiological pathways leading to inhibition of platelet 
activation (31). Preincubation of platelets with cicaprost 
resulted in inhibition of thrombin- and Pam3Cys- 
Ser(Lys)4-induced platelet aggregation and serotonin 
release (Fig. 7). The inhibitory effects of cicaprost 
toward the action of thrombin were more pronounced 
than the inhibitory effects toward Pam3CysSer(Ly&- 
induced platelet activation. Because stimulation of CAMP 
production by different mechanisms is known to inhibit 
tyrosine phosphorylation and [Ca2+l, elevation induced 
by different stimuli in platelets (10,22,31), we addition- 
ally tested the effect of cicaprost on tyrosine phosphory- 
lation and [Ca2+]i elevation induced by Pam3CysSer(Ly& 
and thrombin (Fig. 7, C and D). Although thrombin- 
induced tyrosine phosphorylation was totally abolished 
by cicaprost, the rise in [Caz+]i produced by thrombin 
and the effects of Pam3CysSer(LysJ4 on [Ca2+]i and 
tyrosine phosphorylation were markedly reduced by the 
prostacyclin analogue cicaprost. 
DISCUSSION 
Synthetic lipopeptide analogues of bacterial lipopro- 
tein, which constitutes a major component of the outer 
membrane of gram-negative bacteria, are well known 
activators of B-lymphocytes, macrophages, and neutro- 
phils (3, 12, 28). The data presented here indicate that 
lipopeptides also activate human platelets. The activa- 
tion of platelets was examined by studying the effect of 
lipopeptides on the main platelet responses to stimuli, 
i.e., the aggregation of platelets and the release of 
granule content measured as serotonin secretion from 
[3H]serotonin-loaded platelets. The lipopeptide Pam3- 
CvsSer(LvsId rapidly induced aggregation of platelets 
and secretion of serotonin from platelets (Figs. 1 and 2). 
Effects could be observed at Pam3CysSer(Lys), concen- 
trations of < 1 FM. Half-maximal and maximal effects 
occurred at concentrations of 2-3 and lo-30 PM, 
respectively (Figs. 1 and 2). The maximum response of 
Pam3CysSer(Lys)4 was of similar magnitude to that 
obtained using 1.5 U/ml thrombin, a potent platelet 
stimulus. Platelet activation in response to Pam3Cys- 
Ser(Lys), differed from activation induced by thrombin, 
in that it occurred significantly earlier. 
To exclude the possibility that platelet activation was 
dependent on the positively charged lysine residues of 
Pam3CysSer(Lys)4 and to elucidate which part of the 
lipopeptide molecule is necessary for its biological activ- 
ity, Pam3CysPEG, the lipopeptide Pam3CysAlaGly, and 
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Fig. 6. Influence of genistein on PamsCysSer(Lys)b- and thrombin- 
induced activation of human platelets. A: after preincubation of 
platelets in absence or presence of indicated concentrations of genis- 
tein (G), platelets were incubated without (-1 or with 20 p,M 
Pam&ysSer(Lys)h (P) and 1 U/ml thrombin (T) for further 2 min. 
Thereafter, tyrosine-phosphorylated proteins were detected as de- 
scribed. Shown is autoluminogram of blot with molecular masses 
&Da) of marker proteins on left. B and C: platelets were preincubated 
with indicated concentrations of genistein (control: without genistein) 
and then stimulated with 5 p,M PamsCysSer(Lys)d (B) or with 0.5 
U/ml thrombin (Cl. Platelet aggregation was measured as described in 
MATERIALS AND METHODS. D: serotonin release after addition of vehicle 
(-) or 20 pM Pam&ysSer(Lys)d (P) and 1 U/ml thrombin (T) was 
measured in platelets preincubated in absence or presence of indicated 
concentrations of genistein (G) as described in Fig. 2 and in MATERIALS 
AND METHODS. Serotonin release was measured 2 min after addition of 
stimuli. In all experiments shown, cells were preincubated for 15 min 
with indicated genistein concentrations. 
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Fig. 7. Effect of cicaprost on platelet activation in re- 
sponse to PamaCysSer(Lys)d and thrombin. A and B: effect 
of 1 ~.LM cicaprost (C) on platelet aggregation (A) and 
serotonin release (B) induced by 30 )LM PamaCysSer(Lys)d 
(P) or 1.5 U/ml thrombin (T). Experiments were per- 
3 formed as described in MATERIALS AND METHODS. Platelets 
were incubated with cicaprost for 5 min before addition of -r P- I P-T 
-- 
time [min] 
stimuli. Serotonin release was measured 5 mm after 
addition of stimuli. C: effect of 1 ~.LM cicaprost on tyrosine 
phosphorylation of platelet proteins induced by incubation 
with 30 pM Pam&ysSer(Lys)4 (P) or 1.5 U/ml thrombin 
(T) for 3 min. Shown is autoluminogram of blot with 
molecular masses of marker proteins (kDa) on left. Tyro- 
sine phosphorylation was determined as described. D: 
-1000 
effect of 1 pM cicaprost on rise in [C!a2+], induced by 5 p,M 
2 
Pam&ysSer(Lys)d (P; top) or 1.5 U/ml thrombin (T; 
bottom). [Ca2+l, was determined as described in Fig. 3 and 
c 
-300 "_ 
in MATERIALS AND METHODS. In all experiments shown, Cells 
were preincubated for 5 min with cicaprost. 
27 
(d 
control cicaprost 
94 b 
67 m 
P-T P-T 
. 
control cicaprost 
the hexapeptide CysSer(Lys)4 were employed. PamsCys- Because elevation of [Ca2+]i and tyrosine phosphoryla- 
AlaGly also led to the activation of platelets. However, tion of cellular proteins are important molecular events 
Pam&ysAlaGly-induced platelet activation occurred involved in platelet activation by different stimuli (16, 
more slowly than that induced by PamsCysSer(Lys)d, 29, 30), we studied the effect of lipopeptides on both 
and Pam&ysAlaGly was less potent and less effective parameters. PamaCysSer(Lys)d within seconds led to an 
than PamsCysSer(Lys), (Figs. 1 and 2). Neither Pams- increase in [Ca2+]i (Fig. 3) and to tyrosine phosphoryla- 
Cys, Pam$ysPEG, nor the peptide CysSer(Lys)4 in- tion of cellular proteins (Figs. 4 and 5) in a concentration- 
duced platelet activation (Fig. 4 and Table 1). In addi- dependent manner. Elevation of [Ca2+]i and stimulation 
tion, high concentrations of dilysine (applied at of tyrosine phosphorylation were achieved with half- 
concentrations to 1 mM) were without any effect on maximal and maximal concentrations of N 2-3 and 10 
platelet aggregation and serotonin secretion (data not PM Pams,C!ysSer(Lys)a, respectively (Figs. 3 and 4). The 
shown). Taken together, this indicates that the charac- concentrations are similar to those needed for platelet 
teristic lipid moiety of lipopeptides, consisting of one aggregation and secretion (Figs. 1 and 2). The lipopep- 
amide-linked and two ester-linked fatty acids attached tide PamsCysAlaGly also induced tyrosine phosphoryla- 
to S-(2,3-dihydroxypropyl)-cysteine, is necessary but tion of proteins with molecular masses identical to those 
not sufficient for platelet activation by lipopeptides and found after incubation with PamsCysSer(Lys)( (Fig. 4), 
that the amino acids of the peptide moiety may contrib- but significant effects of Pam&ysAlaGly on [Ca’+]i 
ute to the potency and effectiveness of the lipopeptide- could not be observed (data not shown). Pams- 
induced platelet activation. CysSer(Lys),-induced elevation of [Ca2+]i and tyrosine 
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phosphorylation occurred with a very similar time depen- 
dence and effectiveness (Figs. 3 and 5). These data 
indicate that lipopeptides use common early intracellu- 
lar signal transduction pathways to induce platelet 
activation. The relevance of Pam,CysSer(Lys),-induced 
tyrosine phosphorylation for platelet activation is dem- 
onstrated by the finding that the tyrosine kinase inhibi- 
tor genistein, which largely inhibited tyrosine phosphor- 
ylation in response to PamSCysSer(Lys)d and thrombin, 
inhibited platelet aggregation and serotonin secretion in 
a concentration-dependent manner in response to both 
stimuli (Fig. 6). This is in line with earlier studies 
showing that tyrosine phosphorylation is implicated in 
platelet aggregation and secretion of serotonin (17, 26). 
In addition, tyrosine phosphorylation of a subset of 
proteins phosphorylated on tyrosine residues in the 
course of platelet activation has been shown to be 
dependent on the activation of glycoprotein IIb-IIIa and 
subsequent fibrinogen binding (8, 10). 
Platelet activation by Pam&ysSer( Lys)4 also re- 
sembled thrombin-induced activation with regard to its 
dependence on the presence of extracellular calcium. 
Although tyrosine phosphorylation induced by both 
stimuli was only slightly inhibited in the absence of 
extracellular calcium (data not shown), platelet aggrega- 
tion and [Ca”+]i elevation were markedly reduced in the 
absence of extracellular calcium (Figs. 1 and 3). Simi- 
larly, elevation of the intracellular CAMP concentration 
via the prostacyclin receptor by cicaprost inhibited both 
Pam&ysSer( Ly&- and thrombin-induced platelet acti- 
vation (Fig. 7). These data indicate that lipopeptide- 
induced platelet activation is susceptible to the action of 
a physiological platelet inhibitor. 
Although the effects of both thrombin and Pamy- 
CysSer(Ly& are mediated at least in part by similar or 
identical mechanisms, it is obvious that the activation of 
platelets by lipopeptide and by thrombin exhibit slightly 
different susceptibilities toward the action of cicaprost 
and genistein and toward the removal of extracellular 
calcium. Genistein more effectively inhibited the effects 
of Pam$ysSer(Ly& (Fig 6), and cicaprost more effec- 
tively inhibited the effects of thrombin (Fig. 7). In 
addition, the thrombin-induced aggregation was more 
susceptible to the removal of extracellular calcium than 
the lipopeptide-induced aggregation (Fig. 1). 
So far, it is not clear whether lipopeptides activate 
platelets via a surface receptor or whether lipopeptides 
exert their effects independently of a surface receptor. 
The latter possibility appears to be conceivable, since 
studies carried out by electron energy loss spectroscopy 
(32) indicate that lipopeptide can quickly enter the cell. 
Because lipopeptides lead to the activation of early 
signal transduction pathways identical to thrombin, the 
site of a receptor-independent platelet activation by 
lipopeptides can be assumed to be located at an early 
step of the pathways leading to platelet activation. The 
direct activation of guanine nucleotide-binding proteins 
(G proteins) b y 1 ipopeptides may represent a possible 
mechanism for the lipopeptide effects (28). In any case, 
the molecular site of lipopeptide action remains to be 
elucidated. 
Whether lipoprotein or lipopeptides, which are a main 
component of the outer membrane of gram-negative 
bacteria and which occur in murein-bound and free 
form, can be released from bacteria in considerable 
quantities and whether they may play a pathophysiologi- 
cal role in inflammatory processes due to gram-negative 
bacteria or in gram-negative sepsis is as yet not known. 
The direct activation of platelets by lipopeptides could 
contribute to the known platelet activation in the course 
of endotoxemia (15, 18, 33). However, this speculation 
needs further support by the use of in vivo models. 
Interestingly, lipid A, which is also derived from gram- 
negative bacteria and which shows some structural 
similarities to lipopeptides (2 amide- and 2 ester-linked 
hydroxy fatty acids to a glucosamine backbone in lipid A 
vs. 2 ester- and 1 amide-linked palmitic acids in lipopep- 
tides), has also been shown to activate platelets (11, 24, 
25) 
In summary, our data clearly demonstrate that lipo- 
peptide analogues of bacterial lipoprotein are capable of 
full pl .atelet activation and support the view that lipopep- 
tides are activators of various types of hematopoietic 
cells. 
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